COVID-19 and thrombosis: From bench to bedside

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in cardiovascular medicine 2021-04, Vol.31 (3), p.143-160
Hauptverfasser:	Ali, Mohammad A.M., Spinler, Sarah A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants - therapeutic use Antioxidants Blood platelets Coronaviruses COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 Drug Treatment Disease Drug therapy Endothelium Fibrinolytic Agents - therapeutic use Hospitalization Humans Infections Influenza Intensive care Lungs Multisystem inflammatory syndrome in children Nitric oxide Oxidative stress SARS-CoV-2 - pathogenicity Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thromboembolism - drug therapy Thromboembolism - virology Thrombosis Thrombosis - diagnosis Thrombosis - drug therapy Thrombosis - virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!